Canada has approved lecanemab as a treatment for people with early Alzheimer’s disease, giving patients access to one of the first medicines designed to slow the disease rather than simply ease symptoms.
The approval has generated hope because Alzheimer’s disease affects millions of people worldwide and currently has no cure. However, experts say the benefits of the drug are relatively small, while the treatment itself is complicated, expensive, and carries important safety risks.
An article published in the Canadian Medical Association Journal explains what doctors, patients, and families should know before deciding whether lecanemab is the right choice.
Alzheimer’s disease gradually destroys memory, thinking, and the ability to perform everyday tasks. One of the main biological changes in the disease is the buildup of a protein called amyloid in the brain.
Lecanemab is a laboratory-made antibody that attaches to amyloid and helps remove some of these deposits. Scientists hope that reducing amyloid will slow the progression of the disease, although it does not stop or cure Alzheimer’s.
Clinical studies found that patients receiving lecanemab experienced a modest slowing of cognitive decline compared with those who received a placebo.
While this result was statistically significant, many experts point out that the improvement was relatively small. It remains uncertain how much this difference changes a person’s daily life, independence, or the burden on caregivers over the long term.
The treatment is also demanding. Patients must first be diagnosed with early Alzheimer’s disease and have amyloid confirmed through either a PET brain scan or examination of cerebrospinal fluid obtained by lumbar puncture. Eligible patients then receive intravenous infusions every two weeks and undergo regular MRI scans to watch for possible side effects.
One of the biggest concerns is a complication known as amyloid-related imaging abnormalities, or ARIA. As amyloid is removed from the brain, some patients develop temporary brain swelling or small areas of bleeding.
Many cases cause no symptoms, but others may produce headaches, confusion, dizziness, vision changes, seizures, or more serious complications. Careful monitoring is therefore essential throughout treatment.
Cost is another major challenge. In Canada, treatment costs about 35,000 to 40,000 Canadian dollars each year for every patient. At present, the drug is approved but not publicly funded, and many provinces have not decided whether they will provide insurance coverage. This means many patients could face substantial out-of-pocket expenses.
Because of these uncertainties, the authors encourage doctors to use shared decision-making. Rather than automatically recommending or rejecting treatment, clinicians should discuss the expected benefits, possible harms, monitoring requirements, financial costs, and the patient’s personal goals.
Some people may value even a small delay in disease progression enough to accept the risks, while others may decide to wait for stronger evidence or newer therapies.
Researchers continue studying whether earlier treatment, combination therapies, or future anti-amyloid drugs may produce larger benefits. Additional long-term data are also needed to determine whether slowing disease progression ultimately preserves independence or improves quality of life.
The article was published in the Canadian Medical Association Journal.
This article provides a balanced interpretation of lecanemab by emphasizing both its promise and its limitations. The evidence suggests the drug can slow Alzheimer’s progression, but the effect is modest and comes with significant financial, medical, and logistical challenges.
Rather than presenting the treatment as a breakthrough for everyone, the authors argue that decisions should be individualized. This balanced approach is valuable because it helps patients make informed choices while scientists continue gathering stronger long-term evidence.
If you care about Alzheimer’s disease, please read studies about the protective power of dietary antioxidants against Alzheimer’s, and eating habits linked to higher Alzheimer’s risk.
For more health information, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
Source: University of Toronto.
